Year: 2009
Type: erratum
Abstract: Large parts of the text in 'European S3-Guidelines on the systemic treatment of psoriasis vulgaris' 1 are background texts which are helpful to get an overview on the intervention or drug.Despite several review processes some inconsistency and errors might remain.In the following erratum we point out some errors of this guideline that might lead to: (i) an incorrect interpretation of the safety of some products compared to others, or (ii) incorrect dosing.These background text errors do not have an impact on the evidence-based recommendations for the efficacy.The corrections are as follows:Page 31: right column, line 11 To be added as an additional sentence: However, with adalimumab being the newest available biologic at present there is insufficient long-term data on the safety of this drug in patients with plaque-type psoriasis.Page 34: table 27, line 4 Recommended maintenance dose 2 • 25 or 2 • 50 mg weekly To read: Recommended maintenance dose 2 • 25 or 1 • 50 mg weekly Page 35: left column, line 4-5 If PASI 75 (or minimum PASI 50) is not achieved after 12 weeks: 2 • 50 mg weekly up to 24 weeks To read: If PASI 75 (or minimum PASI 50) is not achieved after 12 weeks: 1 • 50 mg weekly up to 24 weeks; enbrel may also be used beyond 24 weeks in some patients
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4232863851
